Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium

Hepatology

Volumn 62, Issue 5, 2015, Pages 1551-1562

  Scirpo, Roberto ^a,b   Fiorotto, Romina ^a   Villani, Ambra ^a   Amenduni, Mariangela ^a   Spirli, Carlo ^a   Strazzabosco, Mario ^a,b  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEXTRAN SULFATE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; POLYPEPTIDE; ROSIGLITAZONE; CYTOKINE; I KAPPA B; I KAPPA B KINASE ALPHA; NFKBIA PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BILIARY TRACT DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS BILIARY EPITHELIUM; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; CYTOKINE RELEASE; ENHANCER REGION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STIMULATION; WILD TYPE; AGONISTS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CHOLANGITIS; CYSTIC FIBROSIS; EPITHELIUM; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; CHOLANGITIS; CYSTIC FIBROSIS; CYTOKINES; EPITHELIUM; I-KAPPA B PROTEINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, INBRED CFTR; NF-KAPPA B; NF-KAPPAB INHIBITOR ALPHA; PPAR GAMMA;

EID: 84945494445     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28000     Document Type: Article

References (48)

1. Riordan JR. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol 1993;55:609-630.
2. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
3. Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis 2001;21:471-488.
4. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. J Clin Gastroenterol 2005;39:S90-S102.
5. Colombo C, Battezzati PM. Liver involvement in cystic fibrosis: primary organ damage or innocent bystander? J Hepatol 2004;41:1041-1044.
6. Colombo C, Battezzati PM, Strazzabosco M, Podda M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis 1998;18:227-235.
7. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012;18:509-519.
8. Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007;292:L383-L395.
9. Venkatakrishnan A, Stecenko AA, King G, Blackwell TR, Brigham KL, Christman JW, et al. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;23:396-403.
10. Verhaeghe C, Delbecque K, de Leval L, Oury C, Bours V. Early inflammation in the airways of a cystic fibrosis foetus. J Cyst Fibros 2007;6:304-308.
11. Fiorotto R, Scirpo R, Trauner M, Fabris L, Hoque R, Spirli C, et al. Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-kappaB-mediated inflammatory response in mice. Gastroenterology 2011;141:1498-1508.
12. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007;13:529-536.
13. Fiorotto R, Spirli C, Fabris L, Cadamuro M, Okolicsanyi L, Strazzabosco M. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007;133:1603-1613.
14. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-688.
15. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-839.
16. Tata JR. Signalling through nuclear receptors. Nat Rev Mol Cell Biol 2002;3:702-710.
17. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470-477.
18. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-759.
19. Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 2006;6:44-55.
20. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010;10:365-376.
21. Harmon GS, Lam MT, Glass CK. PPARs and lipid ligands in inflammation and metabolism. Chem Rev 2011;111:6321-6340.
22. Mandard S, Patsouris D. Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res 2013;2013:613864.
23. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005;122:707-721.
24. Firrincieli D, Zuniga S, Poupon R, Housset C, Chignard N. Role of nuclear receptors in the biliary epithelium. Dig Dis 2011;29:52-57.
25. Spirli C, Fiorotto R, Song L, Santos-Sacchi J, Okolicsanyi L, Masier S, et al. Glibenclamide stimulates fluid secretion in rodent cholangiocytes through a cystic fibrosis transmembrane conductance regulator-independent mechanism. Gastroenterology 2005;129:220-233.
26. Xia X, Jung D, Webb P, Zhang A, Zhang B, Li L, et al. Liver X receptor beta and peroxisome proliferator-activated receptor delta regulate cholesterol transport in murine cholangiocytes. Hepatology 2012;56:2288-2296.
27. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121-141.
28. Harmon GS, Dumlao DS, Ng DT, Barrett KE, Dennis EA, Dong H, et al. Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice. Nat Med 2010;16:313-318.
29. Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009;91:791-795.
30. Giudetti AM, Cagnazzo R. Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases. Prostaglandins Other Lipid Mediat 2012;99:57-67.
31. Ott J, Hiesgen C, Mayer K. Lipids in critical care medicine. Prostaglandins Leukot Essent Fatty Acids 2011;85:267-273.
32. Stulnig TM. Immunomodulation by polyunsaturated fatty acids: mechanisms and effects. Int Arch Allergy Immunol 2003;132:310-321.
33. McKinnon B, Bersinger NA, Mueller MD. Peroxisome proliferating activating receptor gamma-independent attenuation of interleukin 6 and interleukin 8 secretion from primary endometrial stromal cells by thiazolidinediones. Fertil Steril 2012;97:657-664.
34. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002;41:6640-6650.
35. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996;87:13-20.
36. -/- mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol 2004;287:G491-G496.
37. Verhaeghe C, Remouchamps C, Hennuy B, Vanderplasschen A, Chariot A, Tabruyn SP, et al. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem Pharmacol 2007;73:1982-1994.
38. Dekkers JF, van der Ent CK, Kalkhoven E, Beekman JM. PPARgamma as a therapeutic target in cystic fibrosis. Trends Mol Med 2012;18:283-291.
39. Perez A, van Heeckeren AM, Nichols D, Gupta S, Eastman JF, Davis PB. Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol 2008;295:L303-L313.
40. -/- mice. J Pediatr Gastroenterol Nutr 2006;42:275-281.
41. Al-Turkmani MR, Freedman SD, Laposata M. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 2007;77:309-318.
42. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-569.
43. -/- mice. Proc Natl Acad Sci USA 1999;96:13995-14000.
44. Umunakwe OC, Seegmiller AC. Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase. J Lipid Res 2014;55:1489-1497.
45. Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutr J 2014;13:17.
46. Karak M, Bal NC, Bal C, Sharon A. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug. Curr Diabetes Rev 2013;9:275-285.
47. Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007;1771:926-935.
48. Wright MB, Bortolini M, Tadayyon M, Bopst M. Minireview: Challenges and opportunities in development of PPAR agonists. Mol Endocrinol 2014;28:1756-1768.